Drugs / amoxicillin/clavulanate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05169554 | Dec 2021 → May 2026 | Buruli ulcer disease | Research & Development Agency of Aragón Foundation | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | amoxicillin/clavulanate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05169554 ↗ |
| Known as | AMX/CLV | “Clinical trials are currently evaluating amoxicillin/clavulanate (AMX/CLV) co-administration to reduce treatment duration.” PMID 42104494 ↗ May 2026 |
| Route | Oral | “randomized to two oral regimens: (i) Standard: rifampicin plus clarithromycin therapy for 8 weeks; and (ii) Investigational: standard plus amoxicillin/clavulanate for 4 weeks.” PMID 35804454 ↗ Jul 2022 |